Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion

This is a live story built from multiple sources. It may evolve quickly.

Coverage meter • 1 min window

Back to home Open top source

B bloomberg.com

What’s included

Top recent items from this story.

1 items • 1 unique links

Bloomberg Technology 18 hours ago • bloomberg.com

Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion

Novartis AG agreed to buy British biotech Myricx Bio for as much as $1.5 billion, adding an experimental cancer drug designed to deliver more potent treatments directly to tumors while limiting damage to healthy cells.

Open